- DNA isolations – Blood or Bone Marrow specimens
- All isolations include full quality control parameters measured.
- Nanodrop concentration, 260/280
- Fluorescent concentration (dsDNA)
- Each sample that has DNA Isolation performed will have an accompanying Extraction Summary Report provided to the ordering entity.
- The high-quality control parameters ensure that downstream processes (i.e., PCR, NGS, WGS, etc.) have optimal opportunity for success.
- All isolations include full quality control parameters measured.
- Plasma Separation – Whole Blood specimens
- Sample Storage and/or Sample forwarding to reference laboratory for validated confirmatory testing
- ALTseq – Rapid Whole Genome Sequencing for Cancer
- In the world of cancer, time is of the essence. Having access to rapid WGS to characterize the disease in a fraction of the time it takes to perform standard methodologies, such as Flow Cytometry, Cytogenetics, Fluorescent in situ Hybridization, and PCR, will be life-changing for cancer patients and their families. The sooner the detailed genomic characteristics of a patient’s disease can be identified, the faster they can begin customized, targeted, precision therapies to give them the best chance at survival.
- TGen Clinical Laboratory will be utilizing the Illumina NovaSeq X Plus to perform the ALTseq Assay
- The Illumina NovaSeq X Plus was released in the spring of 2023 and represents the next evolution of their flagship Sequencing by Synthesis (SBS) technology with the incorporation of XLEAP-SBS chemistry. Like many instruments from Illumina, this system is highly flexible with two different sequencing positions that can each independently sequence one of the compatible flow cell types (1.5B, 10B, 25B).
- The flexibility provided by the NovaSeq X Plus will enable TCL to provide a rapid turnaround time of 48 hours from the moment the patient specimen comes into the lab until the time a report is available to the ordering physician.
Download ALTseq Assay Description